Equities Analysts Offer Predictions for SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Solid Biosciences in a report released on Monday, March 10th. HC Wainwright analyst A. He now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.86). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at $1.14 EPS.

A number of other brokerages also recently weighed in on SLDB. JMP Securities began coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They issued an "outperform" rating and a $15.00 price target on the stock. Wedbush began coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an "outperform" rating and a $16.00 price target on the stock. Citizens Jmp raised shares of Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. Truist Financial began coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, JPMorgan Chase & Co. cut their price target on shares of Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $15.80.

Remove Ads

Solid Biosciences Price Performance

SLDB opened at $5.61 on Wednesday. The company has a market capitalization of $428.15 million, a price-to-earnings ratio of -1.85 and a beta of 1.98. The firm's fifty day moving average price is $4.09 and its two-hundred day moving average price is $5.50. Solid Biosciences has a 1 year low of $2.88 and a 1 year high of $15.05.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SLDB. JPMorgan Chase & Co. increased its position in shares of Solid Biosciences by 9,393.8% in the fourth quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after purchasing an additional 945,863 shares during the last quarter. Redmile Group LLC bought a new position in shares of Solid Biosciences in the fourth quarter worth approximately $2,461,000. Point72 Asset Management L.P. increased its position in shares of Solid Biosciences by 292.8% in the third quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company's stock worth $3,088,000 after purchasing an additional 330,234 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Solid Biosciences by 270.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 264,069 shares of the company's stock worth $1,056,000 after purchasing an additional 192,714 shares during the last quarter. Finally, Trexquant Investment LP increased its position in shares of Solid Biosciences by 256.9% in the fourth quarter. Trexquant Investment LP now owns 194,281 shares of the company's stock worth $777,000 after purchasing an additional 139,851 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.